ReviewMetabolic brain disease2026
From bench to bedside: Emerging therapeutics for alzheimer's disease in clinical trials.
Review in Metabolic brain disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a neurodegenerative disease characterized by cognitive declination, neuronal loss, & multifaceted pathological mechanisms. Despite extensive scientific research, no definitive cure exists, but recent advancements in clinical trials highlight promising therapeutic strategies targeting multiple pathways involved in AD progression. Early-phase trials (Phases I and II) focus primarily on amyloid-beta (Aβ) and tau pathologies, with monoclonal antibodies like Aducanumab, Lacanemab, and Remternetug targeting Aβ clearance, while tau-directed agents such as E2814 and Bepranemab aim to reduce neurofibrillary tangle formation. Additionally, some novel approaches addressing neuroinflammation, bioenergetic disturbances, neurotransmitter modulation, and synaptic plasticity are emerging. In Phase III, late-stage candidates like Aducanumab, Donanemab, and Lecanemab have advanced, with some receiving regulatory approval, though their long-term clinical efficacy remains under evaluation. Phase IV studies further assess the long-term safety & effectiveness of approved treatments in real world populations. The evolving landscape of AD therapeutics underscores a paradigm shift towards combination therapies and personalized medicine, recognizing AD as a multifactorial disorder.
Indexed as
Identifiers
41848892What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.